Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
Eosinophils have been identified as a prognostic marker in immunotherapy of melanoma and suggested to contribute to anti-tumor host defense. However, the influence of immune checkpoint inhibitors (ICI) on the eosinophil population is poorly studied. Here, we applied routine laboratory tests, multico...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1727116 |
| _version_ | 1818835596885360640 |
|---|---|
| author | Sonja C. S. Simon Xiaoying Hu Jasper Panten Mareike Grees Simon Renders Daniel Thomas Rebekka Weber Torsten J. Schulze Jochen Utikal Viktor Umansky |
| author_facet | Sonja C. S. Simon Xiaoying Hu Jasper Panten Mareike Grees Simon Renders Daniel Thomas Rebekka Weber Torsten J. Schulze Jochen Utikal Viktor Umansky |
| author_sort | Sonja C. S. Simon |
| collection | DOAJ |
| description | Eosinophils have been identified as a prognostic marker in immunotherapy of melanoma and suggested to contribute to anti-tumor host defense. However, the influence of immune checkpoint inhibitors (ICI) on the eosinophil population is poorly studied. Here, we applied routine laboratory tests, multicolor flow cytometry, RNA microarray analysis, and bio-plex assay to analyze circulating eosinophils and related serum inflammatory factors in 32 patients treated with pembrolizumab or the combination of nivolumab and ipilimumab. We demonstrated that clinical responses to ICI treatment were associated with an eosinophil accumulation in the peripheral blood. Moreover, immunotherapy led to the alteration of the eosinophil genetic and activation profile. Elevated serum concentrations of IL-16 during ICI treatment were found to be associated with increased frequencies of eosinophils in the peripheral blood. Using immunohistochemistry, we observed an enhanced eosinophil degranulation and a positive correlation between eosinophil and CD8+ T cell infiltration of tumor tissues from melanoma patients treated with ICI. Our findings highlight additional mechanisms of ICI effects and suggest the level of eosinophils as a novel predictive marker for melanoma patients who may benefit from this immunotherapy. |
| first_indexed | 2024-12-19T02:53:14Z |
| format | Article |
| id | doaj.art-929050eefb31430384cff2eee14ffd5e |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-19T02:53:14Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-929050eefb31430384cff2eee14ffd5e2022-12-21T20:38:29ZengTaylor & Francis GroupOncoImmunology2162-402X2020-01-019110.1080/2162402X.2020.17271161727116Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitorsSonja C. S. Simon0Xiaoying Hu1Jasper Panten2Mareike Grees3Simon Renders4Daniel Thomas5Rebekka Weber6Torsten J. Schulze7Jochen Utikal8Viktor Umansky9German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)Heidelberg UniversityGerman Cancer Research Center (DKFZ)German Cancer Research Center (DKFZ)Eosinophils have been identified as a prognostic marker in immunotherapy of melanoma and suggested to contribute to anti-tumor host defense. However, the influence of immune checkpoint inhibitors (ICI) on the eosinophil population is poorly studied. Here, we applied routine laboratory tests, multicolor flow cytometry, RNA microarray analysis, and bio-plex assay to analyze circulating eosinophils and related serum inflammatory factors in 32 patients treated with pembrolizumab or the combination of nivolumab and ipilimumab. We demonstrated that clinical responses to ICI treatment were associated with an eosinophil accumulation in the peripheral blood. Moreover, immunotherapy led to the alteration of the eosinophil genetic and activation profile. Elevated serum concentrations of IL-16 during ICI treatment were found to be associated with increased frequencies of eosinophils in the peripheral blood. Using immunohistochemistry, we observed an enhanced eosinophil degranulation and a positive correlation between eosinophil and CD8+ T cell infiltration of tumor tissues from melanoma patients treated with ICI. Our findings highlight additional mechanisms of ICI effects and suggest the level of eosinophils as a novel predictive marker for melanoma patients who may benefit from this immunotherapy.http://dx.doi.org/10.1080/2162402X.2020.1727116melanomaimmune checkpoint inhibitorseosinophilst cells |
| spellingShingle | Sonja C. S. Simon Xiaoying Hu Jasper Panten Mareike Grees Simon Renders Daniel Thomas Rebekka Weber Torsten J. Schulze Jochen Utikal Viktor Umansky Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors OncoImmunology melanoma immune checkpoint inhibitors eosinophils t cells |
| title | Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| title_full | Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| title_fullStr | Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| title_full_unstemmed | Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| title_short | Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| title_sort | eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors |
| topic | melanoma immune checkpoint inhibitors eosinophils t cells |
| url | http://dx.doi.org/10.1080/2162402X.2020.1727116 |
| work_keys_str_mv | AT sonjacssimon eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT xiaoyinghu eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT jasperpanten eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT mareikegrees eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT simonrenders eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT danielthomas eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT rebekkaweber eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT torstenjschulze eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT jochenutikal eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors AT viktorumansky eosinophilaccumulationpredictsresponsetomelanomatreatmentwithimmunecheckpointinhibitors |